Cargando…
A bioavailable cathepsin S nitrile inhibitor abrogates tumor development
BACKGROUND: Cathepsin S has been implicated in a variety of malignancies with genetic ablation studies demonstrating a key role in tumor invasion and neo-angiogenesis. Thus, the application of cathepsin S inhibitors may have clinical utility in the treatment of cancer. In this investigation, we appl...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839156/ https://www.ncbi.nlm.nih.gov/pubmed/27097645 http://dx.doi.org/10.1186/s12943-016-0513-7 |
_version_ | 1782428104240660480 |
---|---|
author | Wilkinson, Richard D. A. Young, Andrew Burden, Roberta E. Williams, Rich Scott, Christopher J. |
author_facet | Wilkinson, Richard D. A. Young, Andrew Burden, Roberta E. Williams, Rich Scott, Christopher J. |
author_sort | Wilkinson, Richard D. A. |
collection | PubMed |
description | BACKGROUND: Cathepsin S has been implicated in a variety of malignancies with genetic ablation studies demonstrating a key role in tumor invasion and neo-angiogenesis. Thus, the application of cathepsin S inhibitors may have clinical utility in the treatment of cancer. In this investigation, we applied a cell-permeable dipeptidyl nitrile inhibitor of cathepsin S, originally developed to target cathepsin S in inflammatory diseases, in both in vitro and in vivo tumor models. METHODS: Validation of cathepsin S selectivity was carried out by assaying fluorogenic substrate turnover using recombinant cathepsin protease. Complete kinetic analysis was carried out and true K(i) values calculated. Abrogation of tumour invasion using murine MC38 and human MCF7 cell lines were carried out in vitro using a transwell migration assay. Effect on endothelial tube formation was evaluated using primary HUVEC cells. The effect of inhibitor in vivo on MC38 and MCF7 tumor progression was evaluated using cells propagated in C57BL/6 and BALB/c mice respectively. Subsequent immunohistochemical staining of proliferation (Ki67) and apoptosis (TUNEL) was carried out on MCF7 tumors. RESULTS: We confirmed that this inhibitor was able to selectively target cathepsin S over family members K, V, L and B. The inhibitor also significantly reduced MC38 and MCF7 cell invasion and furthermore, significantly reduced HUVEC endothelial tubule formation in vitro. In vivo analysis revealed that the compound could significantly reduce tumor volume in murine MC38 syngeneic and MCF7 xenograft models. Immunohistochemical analysis of MCF7 tumors revealed cathepsin S inhibitor treatment significantly reduced proliferation and increased apoptosis. CONCLUSIONS: In summary, these results highlight the characterisation of this nitrile cathepsin S inhibitor using in vitro and in vivo tumor models, presenting a compound which may be used to further dissect the role of cathepsin S in cancer progression and may hold therapeutic potential. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12943-016-0513-7) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4839156 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-48391562016-04-22 A bioavailable cathepsin S nitrile inhibitor abrogates tumor development Wilkinson, Richard D. A. Young, Andrew Burden, Roberta E. Williams, Rich Scott, Christopher J. Mol Cancer Research BACKGROUND: Cathepsin S has been implicated in a variety of malignancies with genetic ablation studies demonstrating a key role in tumor invasion and neo-angiogenesis. Thus, the application of cathepsin S inhibitors may have clinical utility in the treatment of cancer. In this investigation, we applied a cell-permeable dipeptidyl nitrile inhibitor of cathepsin S, originally developed to target cathepsin S in inflammatory diseases, in both in vitro and in vivo tumor models. METHODS: Validation of cathepsin S selectivity was carried out by assaying fluorogenic substrate turnover using recombinant cathepsin protease. Complete kinetic analysis was carried out and true K(i) values calculated. Abrogation of tumour invasion using murine MC38 and human MCF7 cell lines were carried out in vitro using a transwell migration assay. Effect on endothelial tube formation was evaluated using primary HUVEC cells. The effect of inhibitor in vivo on MC38 and MCF7 tumor progression was evaluated using cells propagated in C57BL/6 and BALB/c mice respectively. Subsequent immunohistochemical staining of proliferation (Ki67) and apoptosis (TUNEL) was carried out on MCF7 tumors. RESULTS: We confirmed that this inhibitor was able to selectively target cathepsin S over family members K, V, L and B. The inhibitor also significantly reduced MC38 and MCF7 cell invasion and furthermore, significantly reduced HUVEC endothelial tubule formation in vitro. In vivo analysis revealed that the compound could significantly reduce tumor volume in murine MC38 syngeneic and MCF7 xenograft models. Immunohistochemical analysis of MCF7 tumors revealed cathepsin S inhibitor treatment significantly reduced proliferation and increased apoptosis. CONCLUSIONS: In summary, these results highlight the characterisation of this nitrile cathepsin S inhibitor using in vitro and in vivo tumor models, presenting a compound which may be used to further dissect the role of cathepsin S in cancer progression and may hold therapeutic potential. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12943-016-0513-7) contains supplementary material, which is available to authorized users. BioMed Central 2016-04-21 /pmc/articles/PMC4839156/ /pubmed/27097645 http://dx.doi.org/10.1186/s12943-016-0513-7 Text en © Wilkinson et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Wilkinson, Richard D. A. Young, Andrew Burden, Roberta E. Williams, Rich Scott, Christopher J. A bioavailable cathepsin S nitrile inhibitor abrogates tumor development |
title | A bioavailable cathepsin S nitrile inhibitor abrogates tumor development |
title_full | A bioavailable cathepsin S nitrile inhibitor abrogates tumor development |
title_fullStr | A bioavailable cathepsin S nitrile inhibitor abrogates tumor development |
title_full_unstemmed | A bioavailable cathepsin S nitrile inhibitor abrogates tumor development |
title_short | A bioavailable cathepsin S nitrile inhibitor abrogates tumor development |
title_sort | bioavailable cathepsin s nitrile inhibitor abrogates tumor development |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839156/ https://www.ncbi.nlm.nih.gov/pubmed/27097645 http://dx.doi.org/10.1186/s12943-016-0513-7 |
work_keys_str_mv | AT wilkinsonrichardda abioavailablecathepsinsnitrileinhibitorabrogatestumordevelopment AT youngandrew abioavailablecathepsinsnitrileinhibitorabrogatestumordevelopment AT burdenrobertae abioavailablecathepsinsnitrileinhibitorabrogatestumordevelopment AT williamsrich abioavailablecathepsinsnitrileinhibitorabrogatestumordevelopment AT scottchristopherj abioavailablecathepsinsnitrileinhibitorabrogatestumordevelopment AT wilkinsonrichardda bioavailablecathepsinsnitrileinhibitorabrogatestumordevelopment AT youngandrew bioavailablecathepsinsnitrileinhibitorabrogatestumordevelopment AT burdenrobertae bioavailablecathepsinsnitrileinhibitorabrogatestumordevelopment AT williamsrich bioavailablecathepsinsnitrileinhibitorabrogatestumordevelopment AT scottchristopherj bioavailablecathepsinsnitrileinhibitorabrogatestumordevelopment |